Infectious Diseases are a significant burden on public health and economic stability of societies all over the world. The threat posed by infectious diseases is deepened by the continued emergence of new, unrecognised pathogens and the re-emergence of old infectious diseases, creating a never-ending cycle. While the emergence of novel treatments will generate new opportunities, important challenges in clinical trials remain – from managing overall costs to maintaining
strict operational oversight. There is also the challenge of patient recruitment – diagnosis of a disease often takes several days, but patients must be enrolled in a study within 24 hours, and some diseases are seasonally active, appearing and disappearing quickly.

THE CHALLENGES

• Difficulty in finding appropriate patients due to large number of competing trials by many companies
• Large study size – 31% of Phase III trials need 1000+ patients
• Lengthy trials result in challenges for patient recruitment and retention
• KOL / KOI needed to provide expert knowledge for defining actual endpoints – identification of the right lead investigator

OUR SOLUTION

• Global Scientific Networks – ReSViNET, AfricaNET – enable access to more patients
• Our multi-country Primary Care Research Network aids in patient recruitment and retention
• Peer-to-peer Leadership model helps stimulate recruitment and share best practices
• Our in-house Scientific Officers have extensive knowledge of current infectious disease treatment and trial methodology